LEADER 01466nam 2200409 n 450 001 996387207103316 005 20221108052054.0 035 $a(CKB)1000000000618231 035 $a(EEBO)2248500994 035 $a(UnM)99831495 035 $a(UnM)9928279600971 035 $a(EXLCZ)991000000000618231 100 $a19951012d1658 uy | 101 0 $aeng 135 $aurbn||||a|bb| 200 02$aA father's legacy. Sir Henry Slingsbey's instructions to his sonnes. Written a little before his death$b[electronic resource] 210 $aLondon $cprinted J. Grismond$d1658 215 $a3-91, [5] p 300 $aCaption title on p. 5 reads: A father's legacy to his sonnes. 300 $aCaption title on p. 83 reads: His letter to a person of quality, and his late fellow-prisoner. 300 $a(Includes epitaph). 300 $aFirst page blank?. 300 $aReproduction of the original in the British Library. 330 $aeebo-0018 606 $aConduct of life$vEarly works to 1800 606 $aChristian life$vEarly works to 1800 615 0$aConduct of life 615 0$aChristian life 700 $aSlingsby$b Henry$cSir,$f1602-1658.$01010476 801 0$bCu-RivES 801 1$bCu-RivES 801 2$bCStRLIN 801 2$bWaOLN 906 $aBOOK 912 $a996387207103316 996 $aA father's legacy. Sir Henry Slingsbey's instructions to his sonnes. Written a little before his death$92404592 997 $aUNISA LEADER 01232nam a2200349 i 4500 001 991002747209707536 008 070117s2007 riu b 001 0 eng d 020 $a0821839659 024 3 $a9780821839652 035 $ab13574140-39ule_inst 040 $aDip.to Matematica$beng 082 04$a515.724$222 084 $aAMS 47B35 084 $aLC QA1.M286 100 1 $aZhu, Kehe$042653 245 10$aOperator theory in function spaces /$cKehe Zhu 250 $a2nd ed. 260 $aProvidence, R. I. :$bAmerican Mathematical Society,$cc2007 300 $axvi, 348 p. ;$c27 cm 440 0$aMathematical surveys and monographs,$x0076-5376 ;$v138 504 $aIncludes bibliographical references (p. 325-344) and index 650 0$aOperator theory 650 0$aToeplitz operators 650 0$aHankel operators 650 0$aFunctions of complex variables 650 0$aFunction spaces 907 $a.b13574140$b28-01-14$c02-08-07 912 $a991002747209707536 945 $aLE013 47B ZHU11 (2007)$g1$i2013000206721$lle013$op$pE77.72$q-$rl$s- $t0$u1$v0$w1$x0$y.i14620261$z28-11-07 996 $aOperator theory in function spaces$9349081 997 $aUNISALENTO 998 $ale013$b02-08-07$cm$da $e-$feng$griu$h0$i0 LEADER 01342nam 2200325z- 450 001 9910694348903321 005 20231031153401.0 035 $a(CKB)5860000000026664 035 $a(BIP)016420921 035 $a(EXLCZ)995860000000026664 100 $a20220406c2007uuuu -u- - 101 0 $aeng 200 10$aImproving the laboratory experience for America's high school students $ehearing before the Subcommittee on Research and Science Education, Committee on Science and Technology, House of Representatives, One Hundred Tenth Congress, first session, March 8, 2007 215 $a1 online resource (iii, 59 p.) 311 $a0-16-079023-9 517 $aImproving the Laboratory Experience for America's High School Students 606 $aScience$xStudy and teaching (Secondary)$zUnited States 606 $aLaboratories$xCurricula$zUnited States$xEvaluation 606 $aFederal aid to education$zUnited States 610 $aScience 610 $aLaboratories 610 $aFederal aid to education 610 $aEducation 615 0$aScience$xStudy and teaching (Secondary) 615 0$aLaboratories$xCurricula$xEvaluation. 615 0$aFederal aid to education 906 $aBOOK 912 $a9910694348903321 996 $aImproving the laboratory experience for America's high school students$93133497 997 $aUNINA LEADER 04190nam 22005535 450 001 9910254504203321 005 20200629193919.0 010 $a3-319-23422-6 024 7 $a10.1007/978-3-319-23422-9 035 $a(CKB)3710000000494186 035 $a(EBL)4068139 035 $a(SSID)ssj0001585209 035 $a(PQKBManifestationID)16264907 035 $a(PQKBTitleCode)TC0001585209 035 $a(PQKBWorkID)14865966 035 $a(PQKB)11078920 035 $a(DE-He213)978-3-319-23422-9 035 $a(MiAaPQ)EBC4068139 035 $a(PPN)190520833 035 $a(EXLCZ)993710000000494186 100 $a20151022d2016 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aIntegrative Medicine for Breast Cancer $eAn Evidence-Based Assessment /$fby Mark A. Moyad 205 $a1st ed. 2016. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2016. 215 $a1 online resource (401 p.) 300 $aDescription based upon print version of record. 311 $a3-319-23421-8 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aChapter 1 -- Introduction -- Chapter 2 25+ Observations over 25+ years for Surviving & Thriving in the Dietary Supplement Quality Control &/or Perception vs. Reality World -- Chapter 3 -- The Ideal 7-Step Breast Cancer Diet, Lifestyle & Dietary Supplements Program for Prevention/Recurrence: Heart Healthy=Breast Healthy -- Chapter 4 -- S.A.M & Breast Cancer-Focus on Statins, Red Yeast Rice, Sterols & Other Integrative Cholesterol Medicines: The Real ?Natural? Options -- Chapter 5 S.A.M. & BREAST CANCER-Focus on Aspirin & Other Integrative Aspirin-like Medicines: The Real ?Natural? Options -- Chapter 6 S.A.M. & BREAST CANCER-Focus on Metformin & Other Integrative Metformin-Mimic Medicines: The Real ?Natural? Options -- Chapter 7 Rapid Review of Breast Cancer Treatment Side Effects and Dietary Supplement/Integrative Options from A to Z: What helps, harms, or does nothing -- Chapter 8 Supplements/Diet/Other Integrative Method Vernacular & Controversies from A to Z: What is the latest or greatest, or not so great. 330 $aThis book is designed to capture and clinically review the comprehensive database of clinical research articles that support and do not support the utilization of a variety of dietary supplements and other complementary medicines that physicians are exposed to in their daily practice. The growing list of CAM products that could interfere with surgery (anesthesia, bleeding, outcomes?) and/or conventional medicines is very large and is provided in each section of the book. Additionally, the list of dietary supplements that could be utilized to improve quality of life for breast cancer patients is also emphasized. The various sub-specialty groups in breast are adequately represented, which allows for a physician to rapidly and thoroughly investigate their topic of interest regardless of whether the topic is prevention, treatment, or a specific side effect of treatment. The practical nature of this book cannot be overstated. Chapters include a general overview of the CAM agent, whether or not it has data in medicine and oncology, and a list of potential drug interactions and specific clinical scenarios where it can be utilized or discouraged in the specialty. Each chapter also includes a rapid review A to Z table that covers the clinical take home points for each subject reviewed in each chapter. 606 $aOncology 606 $aEndocrinology 606 $aOncology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33160 606 $aEndocrinology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33053 615 0$aOncology. 615 0$aEndocrinology. 615 14$aOncology. 615 24$aEndocrinology. 676 $a610 700 $aMoyad$b Mark A$4aut$4http://id.loc.gov/vocabulary/relators/aut$0755414 906 $aBOOK 912 $a9910254504203321 996 $aIntegrative Medicine for Breast Cancer$92529102 997 $aUNINA